Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.949
+0.038 (4.20%)
At close: Nov 1, 2024, 4:00 PM
0.932
-0.017 (-1.78%)
After-hours: Nov 1, 2024, 7:18 PM EDT
Ocugen Employees
Ocugen had 65 employees as of December 31, 2023. The number of employees decreased by 19 or -22.62% compared to the previous year.
Employees
65
Change (1Y)
-19
Growth (1Y)
-22.62%
Revenue / Employee
$111,738
Profits / Employee
-$690,815
Market Cap
273.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accolade | 2,400 |
Anika Therapeutics | 357 |
Sutro Biopharma | 302 |
AVITA Medical | 207 |
Fate Therapeutics | 181 |
Heron Therapeutics | 126 |
Inozyme Pharma | 59 |
Lexeo Therapeutics | 58 |
OCGN News
- 4 days ago - Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - GlobeNewsWire
- 10 days ago - Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease - GlobeNewsWire
- 15 days ago - Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results - GlobeNewsWire
- 23 days ago - Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial - GlobeNewsWire
- 4 weeks ago - Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa - GlobeNewsWire
- 5 weeks ago - Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference - GlobeNewsWire
- 6 weeks ago - Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm - Business Wire
- 6 weeks ago - Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 - Seeking Alpha